Sweden
· Delayed Price · Currency is SEK Vicore Pharma Holding AB Statistics
Total Valuation
Vicore Pharma Holding AB has a market cap or net worth of SEK 1.98 billion. The enterprise value is 1.60 billion.
| Market Cap | 1.98B |
| Enterprise Value | 1.60B |
Important Dates
The next estimated earnings date is Thursday, February 27, 2025.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vicore Pharma Holding AB has 234.58 million shares outstanding. The number of shares has increased by 28.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 234.58M |
| Shares Change (YoY) | +28.57% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 2.98% |
| Owned by Institutions (%) | 25.28% |
| Float | 192.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.06 |
| PB Ratio | 2.50 |
| P/TBV Ratio | 5.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.15 |
| EV / Sales | 15.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.27
| Current Ratio | 14.27 |
| Quick Ratio | 13.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.61% and return on invested capital (ROIC) is -28.82%.
| Return on Equity (ROE) | -41.61% |
| Return on Assets (ROA) | -26.70% |
| Return on Capital (ROIC) | -28.82% |
| Revenue Per Employee | 3.59M |
| Profits Per Employee | -6.77M |
| Employee Count | 24 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.75% in the last 52 weeks. The beta is 0.68, so Vicore Pharma Holding AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -41.75% |
| 50-Day Moving Average | 7.98 |
| 200-Day Moving Average | 14.22 |
| Relative Strength Index (RSI) | 63.57 |
| Average Volume (20 Days) | 538,841 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vicore Pharma Holding AB had revenue of SEK 104.24 million and -196.45 million in losses. Loss per share was -1.76.
| Revenue | 104.24M |
| Gross Profit | 104.24M |
| Operating Income | -217.72M |
| Pretax Income | -196.80M |
| Net Income | -196.45M |
| EBITDA | -226.64M |
| EBIT | -217.72M |
| Loss Per Share | -1.76 |
Balance Sheet
| Cash & Cash Equivalents | 380.42M |
| Total Debt | n/a |
| Net Cash | 380.42M |
| Net Cash Per Share | 1.62 |
| Equity (Book Value) | 377.74M |
| Book Value Per Share | 3.38 |
| Working Capital | 378.38M |
Cash Flow
| Operating Cash Flow | -181.24M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -208.86% and -188.45%.
| Gross Margin | 100.00% |
| Operating Margin | -208.86% |
| Pretax Margin | -188.79% |
| Profit Margin | -188.45% |
| EBITDA Margin | -217.41% |
| EBIT Margin | -208.86% |
| FCF Margin | n/a |
Dividends & Yields
Vicore Pharma Holding AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.57% |
| Shareholder Yield | -28.57% |
| Earnings Yield | -20.80% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |